<DOC>
	<DOCNO>NCT01762033</DOCNO>
	<brief_summary>This Phase 2a study investigate efficacy , safety tolerability ASONEP™ ( sonepcizumab/LT1009 ) administer intravenously week , every 4 week ( cycle ) , subject refractory renal cell carcinoma ( RCC ) disease progress . Subjects fail 3 prior treatment RCC include vascular endothelial growth factor ( VEGF ) and/or mammalian target rapamycin ( mTOR ) inhibitor tumor surgically remove eligible screening .</brief_summary>
	<brief_title>A Phase 2 Study ASONEP™ Treat Unresectable Refractory Renal Cell Carcinoma</brief_title>
	<detailed_description>LT1009-Onc-002 Phase 2a open-label , multi-center study design evaluate efficacy safety ASONEP ( sonepcizumab/LT1009 ) monotherapy subject advance , unresectable , refractory RCC previously fail 3 therapy , include VEGF and/or mTOR inhibitor . Two cohort enrol total 39 subject . Subjects receive intravenous ( IV ) infusion ASONEP™ 90 minute 24 mg/kg week progression-free survival ( PFS ) assess 8 week treatment . Cohort 1 enroll approximately 22 subject . A second cohort 17 subject enrol least 12 22 subject Cohort 1 demonstrate PFS 8 week . Weekly dose take place date randomization date first document progression date death cause , whichever come first .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<criteria>Unresectable , locally advanced recurrent metastatic RCC Histological cytological confirmation clear cell RCC core tissue biopsy either primary tumor metastatic lesion paraffinembedded tissue specimen prior nephrectomy Measurable disease RECIST 1.1 Had one prior therapy unresectable RCC VEGF/VEGFR target therapy ( sunitinib , sorafenib , VEGFR TKI bevacizumab ) One prior treatment mTOR inhibitor ( everolimus , temsirolimus sirolimus ) unresectable disease permittedPrior immunotherapy ( immunomodulators cytokine , interleukin , vaccine , etc . ) IL2 also permit Male nonpregnant , nonnursing female Life expectancy ≥3 month ECOG performance status 0 , 1 2 Must receive concurrent anticancer therapy Baseline CT MRI scan measurable disease site RECIST 1.1 perform within 2 week Day 0 For subject bone metastasis , baseline bone scan perform within 4 week study entry Adequate organ immune function ( within 7 day Day 0 ) : Hemoglobin &gt; 9 g/dL−Absolute neutrophil count &gt; 1500 cells/uL without growth factors−Platelet count ≥100x10^9/L without transfusion−Serum creatinine &lt; 2.0x ULN creatinine clearance &gt; 40 mL/min−Total bilirubin &lt; 1.5x ULN−AST/ALT &lt; 2.5x ULN ( &lt; 5.0x ULN liver metastasis present ) −INR aPTT &lt; 1.5x ULN Subject lesion arterial spin labeling ( ASL ) MRI ≥2.5cm CT image Must understand , able willing fully comply study procedure Prior treatment &gt; 3 VEGF pathway and/or mTOR inhibitor RC cancer History CNS disease ( spinal cord compression , evidence symptomatic brain leptomeningeal carcinomatosis ) Major surgery within 4 week Day 0 Radiation therapy within 4 week baseline/infusion . Prior palliative radiation metastatic lesion acceptable least one measurable , nonradiated lesion Uncontrolled intercurrent illness include , limited , ongoing active infection require parenteral antibiotic Day 0 Known suspect intolerance hypersensitivity study material excipients Evidence bowel obstruction theoretical possibility GI perforation antiangiogenesis agent Severe hemorrhage within 4 week screen History GI perforation History nonhealing wound include ulcer delay bone fracture Prolonged QTc interval baseline ECG ( &gt; 450 msec male &gt; 470 msec female ) , cardiac dysrhythmias include atrial fibrillation , torsade de pointes , ventricular tachycardia fibrillation , pathologic sinus bradycardia ( &lt; 60 bpm ) , heart block ( exclude 1st degree block , PR interval prolongation ) , congenital long QT syndrome new ST segment elevation depression new Q wave ECG Secondary malignancy within last 5 year , except adequatelytreated basal cell carcinoma , squamous cell skin cancer , superficial bladder tumor , situ cervical cancer Previously enrol sonepcizumab study study subsequently withdraw History alcohol substance abuse within last year Use corticosteroid immunosuppression ( take systemic steroid [ vs. topical ] , least 4 week must pass since last dose ) Growth factor within 1 week screen Serious medical condition might aggravate treatment limit compliance Cerebrovascular accident transient ischemic attack , pulmonary embolism within 6 month prior screen Participation another clinical trial Other severe intercurrent acute chronic medical psychiatric condition laboratory abnormality may increase risk associate study participation study drug administration</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>Renal cell carcinoma</keyword>
	<keyword>Renal cell cancer</keyword>
	<keyword>ASONEP</keyword>
	<keyword>Sonepcizumab</keyword>
</DOC>